Literature DB >> 11401115

Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype.

M Cicoira1, L Zanolla, A Rossi, G Golia, L Franceschini, G Cabrini, A Bonizzato, M Graziani, S D Anker, A J Coats, P Zardini.   

Abstract

OBJECTIVES: The objective of this study was to assess whether the angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism influences the adequacy of the neurohormonal response to ACE inhibitors in patients with chronic heart failure (CHF).
BACKGROUND: The renin-angiotensin-aldosterone system (RAAS) plays an important role in the pathophysiology of CHF, and aldosterone levels closely relate to outcome in patients with CHF. Angiotensin-converting enzyme inhibitors suppress the RAAS, but a significant proportion of patients exhibit elevated serum levels of aldosterone despite long-term administration of apparently adequate doses of these agents.
METHODS: We prospectively studied 132 patients with CHF (ejection fraction <45%) receiving long-term therapy with ACE inhibitors for over six months. Patients taking aldosterone antagonists were excluded from the study. "Aldosterone escape" was defined as being present when plasma aldosterone levels were above the normal range in our laboratory (>42 nmol/L). Patients were then divided into two subgroups according to the presence (group 1) or absence (group 2) of aldosterone escape. Genotype analysis for the ACE I/D polymorphism was performed by polymerase chain reaction.
RESULTS: The prevalence of aldosterone escape in our patients was 10% (13/132). The two groups of patients did not differ regarding the dose of ACE inhibitor, diuretics and their renal function. There was a statistically significant different distribution of genotypes between the two groups, with a higher proportion of DD genotype in group 1 compared with group 2 (62% vs. 24%, p = 0.005).
CONCLUSIONS: Patients with CHF with aldosterone escape have a higher prevalence of DD genotype compared with patients with aldosterone within the normal limits. Angiotensin-converting enzyme gene polymorphism contributes to the modulation and adequacy of the neurohormonal response to long-term ACE-inhibitor administration in CHF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401115     DOI: 10.1016/s0735-1097(01)01237-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  23 in total

1.  Matters of the heart transcriptome: a brief history of cardiovascular genomics.

Authors:  Pilar M Labordé-Lahoz
Journal:  Tex Heart Inst J       Date:  2002

Review 2.  Targeting tissue angiotensin-converting enzyme for imaging cardiopulmonary fibrosis.

Authors:  Omer Aras; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2008-03       Impact factor: 2.931

3.  The beta1-adrenergic receptor mediates the pharmacogenetic interaction of the ACE D allele and beta-blockers.

Authors:  David C Ishizawar; Karen M Janosko; Jeffrey J Teuteberg; Linda M Cadaret; Michael A Mathier; Dennis M McNamara
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

4.  Aliskiren suppresses atrial electrical and structural remodeling in a canine model of atrial fibrillation.

Authors:  Akira Satoh; Shinichi Niwano; Hiroe Niwano; Jun Kishihara; Yuya Aoyama; Jun Oikawa; Hidehira Fukaya; Hideaki Tamaki; Junya Ako
Journal:  Heart Vessels       Date:  2016-07-11       Impact factor: 2.037

Review 5.  The Genetic Challenges and Opportunities in Advanced Heart Failure.

Authors:  Fady Hannah-Shmouni; Sara B Seidelmann; Sandra Sirrs; Arya Mani; Daniel Jacoby
Journal:  Can J Cardiol       Date:  2015-08-21       Impact factor: 5.223

6.  Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats.

Authors:  Devesh Aggarwal; Gaaminepreet Singh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-11-26       Impact factor: 3.000

7.  A common angiotensin-converting enzyme polymorphism and preoperative angiotensin-converting enzyme inhibition modify risk of tachyarrhythmias after congenital heart surgery.

Authors:  Andrew H Smith; English C Flack; Kristie Y Borgman; Jill P Owen; Frank A Fish; David P Bichell; Prince J Kannankeril
Journal:  Heart Rhythm       Date:  2014-01-01       Impact factor: 6.343

Review 8.  Genomic variation and neurohormonal intervention in heart failure.

Authors:  Dennis M McNamara
Journal:  Heart Fail Clin       Date:  2010-01       Impact factor: 3.179

Review 9.  Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: implications in heart failure management.

Authors:  Amber L Beitelshees; Issam Zineh
Journal:  Heart Fail Rev       Date:  2008-03-20       Impact factor: 4.214

Review 10.  RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease.

Authors:  Jay Lakkis; Wei X Lu; Matthew R Weir
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.